NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury by Leonard, A. et al.
PUBLISHED VERSION  
   
Anna Victoria Leonard, Emma Thornton, Robert Vink 
NK1 receptor blockade is ineffective in improving outcome following a balloon compression model 
of spinal cord injury 
PLoS One, 2014; 9(5): e98364-1-e98364-15 
 
 
© 2014 Leonard et al. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 



























NK1 Receptor Blockade Is Ineffective in Improving
Outcome following a Balloon Compression Model of
Spinal Cord Injury
Anna Victoria Leonard1*, Emma Thornton1, Robert Vink2
1 School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, 2Division of Health Sciences, University of South Australia, Adelaide, South
Australia, Australia
Abstract
The neuropeptide substance P (SP) is a well-known mediator of neurogenic inflammation following a variety of CNS
disorders. Indeed, inhibition of SP through antagonism of its receptor, the tachykinin NK1 receptor, has been shown to be
beneficial following both traumatic brain injury and stroke. Such studies demonstrated that administration of an NK1
receptor antagonist reduced blood-brain-barrier permeability, edema development and improved functional outcome.
Furthermore, our recent studies have demonstrated a potential role for SP in mediating neurogenic inflammation following
traumatic spinal cord injury (SCI). Accordingly, the present study investigates whether inhibition of SP may similarly play a
neuroprotective role following traumatic SCI. A closed balloon compression injury was induced at T10 in New Zealand White
rabbits. At 30 minutes post-injury an NK1 receptor antagonist was administered intravenously. Animals were thereafter
assessed for blood spinal cord barrier (BSCB) permeability, spinal water content (edema), intrathecal pressure (ITP), and
histological and functional outcome from 5 hours to 2 weeks post-SCI. Administration of an NK1 receptor antagonist was
not effective in reducing BSCB permeability, edema, ITP, or functional deficits following SCI. We conclude that SP mediated
neurogenic inflammation does not seem to play a major role in BSCB disruption, edema development and consequential
tissue damage seen in acute traumatic SCI. Rather it is likely that the severe primary insult and subsequent hemorrhage may
be the key contributing factors to ongoing SCI injury.
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Introduction
Spinal cord injury (SCI) remains a major cause of disability
within society, frequently affecting individuals in the prime of their
life. To date, therapies have very limited efficacy in attenuating
any resultant functional deficits, and accordingly, novel therapeu-
tic approaches are urgently required. SCI is characterized by both
primary and secondary injury mechanisms. While the primary
injury is clearly irreversible, secondary injury mechanisms are
considered reversible and are thus targeted for potential thera-
peutic interventions. Edema is one of the major secondary injury
mechanisms in CNS injury, being considered to significantly
contribute to further potentiation of injury development and tissue
damage. The development of edema following SCI has been well
characterized both within the injury epicentre [1,2,3,4,5,6] and in
the adjacent segments where a delayed rostrocaudal spread of
edema has been demonstrated with time [7,8]. Such edema may
be both vasogenic and cytotoxic in nature, however it has been
hypothesized that the initial edema is predominantly vasogenic in
nature given that blood-spinal cord-barrier (BSCB) disruption is
also present [1,2,9,10,11]. Importantly, increased edema following
injury may lead to raised intrathecal pressure (ITP) [12], which in
turn can result in greater tissue damage, and ultimately profound
functional deficits.
Neurogenic inflammation has recently been shown to play an
important role in the development of edema following a range of
CNS injuries [13,14,15,16,17,18,19,20]. Neurogenic inflammation
is a response of perivascular, unmyelinated afferent nerve fibres to
injury or infection and is typically characterized by vasodilation,
protein extravasation and edema [13,14,21]. The vascular
response is facilitated by the release of neuropeptides such as
substance P (SP) and calcitonin gene related peptide (CGRP). SP is
known to preferentially bind to the tachykinin NK1 receptor,
activation of which results in increased barrier permeability and
edema development [14]. Increased SP immunoreactivity has
been associated with increased blood brain barrier (BBB)
permeability and edema development following both TBI
[13,17] and stroke [16], whilst antagonism of the NK1 receptor
has been shown to reduce BBB permeability and edema, as well as
improve functional outcome [13,17,22]. Furthermore, our recent
investigation following SCI has demonstrated that SP stores are
reduced following injury, indicative of SP release, whilst NK1
receptor immunoreactivity increased [20]. Such results implicate a
role for SP as a mediator of neurogenic inflammation following
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SCI. However, whether inhibition of SP may similarly produce a
neuroprotective effect following SCI has not yet been investigated.
Accordingly, the current study investigates the effect of
administration an NK1 receptor antagonist following a balloon
compression model of SCI. Specifically, this paper will assess SP
immunoreactivity, BSCB permeability, edema, ITP, histological
outcome, and functional outcome from 5 hours to 2 weeks post-
SCI. We have utilized the balloon compression model of SCI due
to its closed nature, thus facilitating development of increased ITP,
and its replication of key primary injury mechanisms in clinical
SCI as previously reported [20,23,24,25].
Materials and Methods
All experimental protocols were conducted according to the
guidelines established by the National Health and Medical
Research Council and were approved by the animal ethics
committees of the University of Adelaide (M-2010-140) and the
Institute of Medical and Veterinary Sciences (98/10), Adelaide,
South Australia.
2.1. Balloon compression model of SCI
New Zealand white rabbits (n = 88) were subject to a balloon
compression spinal cord injury as previously described [26,27].
Briefly, during the 12-hour day cycle, animals were removed from
their home cages and anesthetized via a subcutaneous injection of
Ketamine (2.5 mg/kg) and Domitor (0.25 mg/kg) mixture. Once
a surgical level of anesthesia was achieved, the animal was placed
onto a thermostatically controlled heating pad in the prone
position. Initially, the dorsal surface of the animal’s back was
shaved and a midline incision of approximately 10 cm in length
was made along the spinous processors (approximately T11 – L2).
Paraspinal muscles were retracted and a laminectomy performed.
A balloon catheter (ApexTM MonorailTM 4 mm68 mm, Boston
Scientific) was then advanced approximately 4 cm to T10 and
rapidly inflated using an inflation device (Boston Scientific) to 8
atm of pressure. The balloon remained inflated for a 5-minute
period before being deflated and removed. The muscular wound
was sutured closed followed by closure of the skin with surgical
clips. An additional group of animals were subject to all surgical
procedures except inflation of the balloon catheter (sham; surgery
controls).
2.2. n-acetyl L-tryptophan (NAT)
Animals were randomly assigned to receive the NK1 receptor
antagonist, n-acetyl tryptophan (NAT), or equal volume vehicle
(0.9% saline). NAT was administered intravenously at 30 minutes
post-SCI at 2.5 mg/kg, with this optimal dose of NAT having
been previously determined in studies conducted in our laboratory
[28]. For studies with survival times greater than 24 hours, 2
additional i.v. doses were administered daily on day 1 and 2 post-
SCI.
2.3. BSCB permeability
The Evan’s Blue (EB) dye extravasation method, as previously
described [14], was used to assess BSCB permeability at 5 hours
(vehicle, n = 5; NAT, n= 6) post-SCI (or sham, n= 5). Briefly, 30
minutes prior to perfusion, EB was injected intravenously. The
animals were then saline perfused and the spinal cord dissected
and 10 mm segments cut. Each segment was homogenized and
the absorbance of the supernatant was measured at 610 nm using
a spectrophotometer. The level of extravasated EB within each
tissue sample was then determined using a previously obtained EB
standard curve, and was expressed as ug/mg of spinal cord tissue.
2.4. Edema measurement
Animals were assessed for edema at 3 days post-SCI (NAT and
vehicle; n = 4/group) or sham (n= 5) using the wet weight/dry
weight method as previously described [14]. Briefly, animals were
administered a lethal injection of pentobarbital and the spinal cord
rapidly removed. The spinal cord was cut into 10 mm segments
and the wet weight was obtained. Spinal cord segments were then
oven dried at 100uC for 48 hours before the dry weight was
measured. The percentage of tissue water content was then
calculated using the equation: % Water Content = ((Wet Weight
– Dry Weight)/Wet weight) X 100
2.5. Intrathecal pressure measurement
Animals (vehicle, n = 6; NAT, n= 5; sham, n= 5) underwent a
tracheotomy and the right and left femoral artery were dissected.
The right femoral artery was cannulated and connected to a
syringe pump containing saline, which was administered at 2 ml/h
except when taking a blood sample for blood gas analysis. A
Codman MICROSENSOR ICP probe was inserted into the left
artery to monitor blood pressure. Following balloon compression,
a Codman MICROSENSOR ICP probe was introduced into the
intrathecal space and extended to the injury epicentre. The
Codman probes were connected to an 8 channel Powerlab system
(AD instruments) and the output was viewed live and recorded
with Labchart (AD instruments). Intrathecal pressure was moni-
tored for a 5 hour period. Blood pressure and blood gases were
monitored to ensure physiological parameters were maintained.
2.6. Functional outcome
Animals were randomly assigned to sham, vehicle or NAT
treated groups (n = 6 per group) and were assessed on days 3, 7, 10
and 14 post-SCI for both sensory and motor outcome. A modified
Tarlov Score [23] was used to assess motor function of the
hindlimbs. The criteria were as follows: 0 = No movement; 1 =
minor movement of the hind limb joints; 2 = major movement of
the hind limb joints; 3 = able to stand properly but unable to hop;
4 = able to hop, but not properly; 5 = normal movement. Animals
were scored following a recorded 5-minute monitoring period. In
addition, a forelimb to hindlimb ratio was calculated by recording
the number of hindlimb movements per the first 20 forward
moving forelimb steps. This ratio was then converted into a
percentage.
The sensory outcome test involved applying the tip end of
Dumont #4 fine forceps to the shaved plantar surface of animal’s
hind paw and assessing the withdrawal time. Animals were placed
into an enclosed plastic box with a wire bottom with food provided
as a distraction. The fine forceps were then applied to each hind
paw 10 times with a 30 second interval between each application.
The withdrawal response of the animals to the stimulus was
graded as either; 0 = no response, 1 = weak response (slight
movement of one joint of the hindlimb), 2 = moderate response
(extensive movement of 2 or more joints of the hindlimb), or 3 =
normal response. A sensory score out of 30 was given to each hind
paw.
2.7. Histological outcome
Animals were randomly assigned to sham (n= 11), vehicle
(n = 23) and NAT treated groups (n = 21) and were assessed for
histological outcome using immunohistochemical techniques.
Briefly animals were perfuse fixed with 10% formalin at 5 hours,
24 hours, 3 days, or 2 weeks post-SCI. Spinal cord tissue was then
processed, embedded in paraffin and 5 mm cross sections were cut
for assessment of morphological features (H&E stain), SP (Santa
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Cruz Sc-9758; 1:2000, EDTA retrieval), NK1 receptor (Advanced
Targeting Systems #AB-N33AP; 1:4000, Citrate retrieval),
Albumin (Cappel #0113-0341; 1:20,000), microglia (Griffonia
simplicifolia – Sigma L2140; 1:200), and AQP4 (Abcam Ab9512;
1:200, Citrate retrieval).
All sections underwent a similar immunohistochemical proce-
dure, with all antibodies incubated at room temperature and PBS
washes applied between each antibody. Briefly, sections were de-
waxed, dehydrated and placed in methanol with 30% hydrogen
peroxide. Specified microwave antigen retrieval was performed as
required and sections incubated for 45 min in 3% normal horse
serum. Primary antibody was added overnight before specific
biotinylated secondary antibody (Vector,1:250) was added for 30
minutes. Tertiary streptavidin peroxidase conjugate (SPC; Pierce,
1:1000) was added for 1 hour and the immunocomplex visualised
using 3,39diaminobenzidine (DAB; Sigma) as a chromogen in the
peroxidase reaction.
All sections were scanned at high resolution using the
Hamamatsu Nanozoomer. Slides were viewed using the associated
proprietary viewing software (NDP.view v1.1.27, Hamamatsu).
Qualitative assessments were made by a blinded assessor using a
ranking system (0= no staining to 10= extensive dark staining).
Alternatively, whole sections were exported and assessed using our
previously published color deconvolution method [29].
2.8. Statistical Analysis
All statistical tests were undertaken using GraphPad PRISMH.
Evan’s Blue extravasation, edema, ITP, Plantar prick test, and
color deconvolution were analyzed using a two-way analysis of
variance (ANOVA) followed by Bonferroni post-tests, with data
expressed as mean 6 standard error of the mean (SEM).
Immunohistochemistry ranking and modified Tarlov score were
analyzed using the Kruskal Wallis ANOVA followed by Dunn’s
multiple comparisons test. This data was expressed as the median
and interquartile range (immunohistochemical ranking) or as the
median and individual data points (Tarlov score).
Results
3.1. BSCB Permeability– Evan’s Blue extravasation
Sham animals demonstrated minimal EB extravasation with an
average of 6.9361.25 mg EB/g tissue measured along all segments
of the spinal cord (Figure 1A). After injury, a significant (p,0.001)
increase in EB extravasation to 15.4363.04 mg EB/g tissue was
observed in vehicle treated animals within the injury epicentre at
5 hours post-SCI, with adjacent segments recording similar values
to sham. NAT treated animals had similar EB extravasation to
vehicles within the injury epicentre (p,0.001), however recorded
significantly greater EB values (0.01,p,0.05) in the immediate
adjacent segments when compared to shams. No significant
differences were seen between vehicle and NAT treated groups.
3.2. Edema measurement
The spinal cord tissue water content of sham animals was
65.5562.08% (Figure 1B). By 3 days post-SCI in vehicle treated
animals, spinal cord water content had significantly increased (p,
0.001) to 77.4761.00% in the injury epicentre and to
68.8261.39% and 70.461.56% within the immediate rostral
(p,0.05) and caudal (p,0.001) segments, respectively. NAT
treated animals had a similar edema profile to vehicle treated
animals at this time, although a greater increase was apparent
within the most distal caudal segment of the spinal cord, which was
significant compared to sham (p,0.05).
3.3. Intrathecal pressure measurement
The intrathecal pressure of sham animals was
0.6561.61 mmHg at the beginning of the recording period then
stabilized and reached 3.7561.26 mmHg by the end of monitor-
ing (Figure 1C). An immediate significant increase in ITP was
observed following injury with vehicle treated animals recording
5.3163.98 mmHg (p,0.001) at 30 min post-SCI. ITP continued
to gradually rise, reaching a maximal ITP of 7.3660.79 mmHg by
the end of 5 hour monitoring period (p,0.001). A similar
significant increase in ITP was observed at the beginning of the
monitoring period within the NAT treated group, with a recorded
ITP measurement of 6.8261.48 mmHg (p,0.001). Thereafter, a
gradual increase in ITP was observed in the NAT treated group
reaching a maximal recording of 9.4261.34 mmHg at the end of
the monitoring period (p,0.001). Whilst the NAT treated animals
appear to trend slightly higher, no significant difference was
observed between treatment groups over time.
3.4. Functional outcome
3.4.1. Motor function - Modified Tarlov Scale. Sham
animals demonstrated normal motor function on all assessment
days and ranked 5 (Figure 2A). Following injury, vehicle treated
animals demonstrated a significant decrease in hindlimb motor
function with severe paralysis observed on days 3 and 6 post-SCI.
By day 10 and 14, vehicle treated animals ranked 1 and had
regained some motor function. In contrast, NAT treated animals
had recovered some minor hindlimb joint movement on day 6
post-SCI and accordingly had a significant improvement when
compared to vehicle treated animals (p,0.05). However, from day
10 onwards, vehicle and NAT treated animals both had only
minor motor function as assessed by the Tarlov score.
3.4.2. Motor function - hindlimb to forelimb ratio. The
frequency of the hind limb movement was recorded as the number
of hindlimb movements per 20 forelimb steps (Figure 2B). Sham
animals demonstrated normal movement with every forelimb step
followed by a hindlimb step, resulting in a 100% normal hindlimb
movement. Vehicle treated injured animals showed no hind limb
movement on day 3 and subsequently recorded 0% for the
frequency of hind limb movement. Thereafter, a gradual increase
in the frequency of hindlimb movement was observed, reaching
20615.17% by day 14 post-SCI. As in the Tarlov score, NAT
treated animals demonstrated earlier increases in the frequency of
hindlimb movement with 10.83612.81% recorded on day 6 post-
SCI, and had a higher maximal frequency of movement of
25.83618.82% observed on day 14 post-SCI. However, the
improvement in hindlimb motor function produced by NAT
treatment was only slight and was not significant.
3.4.3. Sensory function – prick test. Sham animals
demonstrated normal sensory function over the 14 day assessment
period, with only a slight deficit observed on day 3 in the left
hindlimb. Such results suggest that the surgical procedure did not
affect sensory function (Figure 2C and 2D). Vehicle treated
animals demonstrated a significant decrease on day 3 post-SCI to
11.7564.57 and 13.0066.38 for the left and right hindlimbs,
respectively (p,0.001). Some spontaneous improvement was
observed over the assessment period and by day 14 the pain
withdrawal score was 17.0064.96 and 16.5064.43 for the left and
right hindlimbs, respectively (p,0.001). NAT animals similarly
demonstrated a significant decrease in sensory function following
injury, obtaining a pain withdrawal score of 13.0062.98 and
10.0064.99 for the left and right hindlimbs, respectively, on day 3
post-SCI (P,0.001). Similarly to vehicle treated animals, NAT
treated animals recorded a slight spontaneous improvement in
sensory function in both hindlimbs during the assessment period
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recording a pain withdrawal score on day 14 post-SCI of 1866.24
and 17.561.71 in the left and right hindlimbs respectively.
3.5. Histological outcome
3.5.1. Morphological features – H&E staining. Sham
animals had normal tissue morphology and architecture (Figure 3).
SCI resulted in focal areas of severe hemorrhage within the injury
epicentre, predominantly within the grey matter, and substantial
tissue disruption at 5 hours. The hemorrhage continued to spread
and was diffusively located through the injury epicentre by
24 hours. Localized hemorrhage was also observed predominantly
within the dorsal aspect of the white matter in the adjacent
segments at this time. By 3 days post-SCI, moderate diffuse
hemorrhage was observed within the injury epicentre, whilst
minor hemorrhage was still apparent within the adjacent
segments. Additionally by this time, loss of tissue morphology
and architecture are clearly evident in the injury epicentre. By 2
weeks post-SCI extensive tissue loss was evident within the injury
Figure 1. The effect of NAT administration on barrier permeability at 5 hours post-SCI was determined by the extent of EB
extravasation (A). The percentage of spinal cord tissue water content was measured to determine the extent of edema development at 3 days
post-SCI (B). The effect of NAT administration on ITP was measured for a 5 hour monitoring period (C). Sham levels indicated by the dashed line in (A)
& (B). *denotes p,0.05, ** denotes p,0.01, *** denotes p,0.001 compared to sham.
doi:10.1371/journal.pone.0098364.g001
Effect of an NK1 Receptor Antagonist following Spinal Cord Injury
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epicentre with minimal white matter sparing and minor hemor-
rhage. The adjacent segments also demonstrated loss of tissue
centred within the grey matter and radiating outwards. No
differences in morphological features were observed between
treatment groups at any time point post-SCI.
Figure 2. The effect of NAT administration on motor and sensory function following SCI. A modified Tarlov score was used to assess
crude motor function (A), data is expressed as the median with individual data points plotted. Whilst a significant improvement was observed at 6
days post-SCI following NAT administration, this improvement was not significantly different to vehicle on days 10 and 14 post-injury. The frequency
of hindlimb movement gradually increased in both treatment groups over time (B). Whilst NAT treated animals demonstrated earlier increases in
movement frequency, no significant difference was observed between groups. A similar significant decrease in sensory function was observed in
both the left (C) and right (D) hindlimbs of both treatment groups. ** denotes p,0.01, *** denotes p,0.001 when compared to sham.# denotes p,
0.05 compared to vehicle.
doi:10.1371/journal.pone.0098364.g002
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3.5.2. Substance P immunoreactivity - Dorsal Horn
region. Sham animals demonstrated a moderate level of SP
immunoreactivity (median = 6) within the grey matter with
particular predominance in lamina I and II of the dorsal horn
(Figure 4). Within the injury epicentre, there was a significant
decrease in SP immunoreactivity in both treatment groups when
compared to sham (p,0.001), with further decreases in both
groups at 24 hours (vehicle = 0 p,0.001; NAT=1 p,0.01) and 3
days post-SCI (p,0.001 for both groups). By 2 weeks, the injury
epicentre in both groups was completely devoid of SP immuno-
reactivity (p,0.001). The loss in SP immunoreactivity within the
adjacent sections was not as pronounced as in the injury epicentre
until day 3 in the 10 mm caudal section (median = 2; p,0.001)
and 2 weeks in the 10 mm rostral section (median = 2).
Interestingly at day 3 within the 10 mm caudal section, NAT
treated animals had greater SP expression, with a median ranking
of 4. Similarly, in the rostral section at 2 weeks, NAT treated
animals recorded a higher median ranking of 4 suggesting NAT
treatment resulted in greater SP immunoreactivity.
3.5.3. Substance P immunoreactivity - Perivascular
region. The perivascular region was assessed within the grey
matter of the spinal cord (Figure 5). The injury epicentre could not
be examined because of severe tissue disruption. Sham animals
demonstrated moderate SP immunoreactivity surrounding the
vasculature with a median of 6. At 5 hours post-SCI a slight
decrease was observed within both adjacent segments in both
treatment groups, with this trend remaining at 24 hours post-SCI.
Interestingly in both adjacent segments, by 3 days post-SCI the
NAT treated group had returned to sham levels, recording a
median ranking of 6. By 2 weeks post-SCI, both treatment groups
demonstrated comparable immunoreactivity to sham levels in the
rostral segment, though remained below sham levels within the
caudal segment. No significant differences were detected between
treatment groups at any time post-SCI.
3.5.4. NK1 immunoreactivity - Grey Matter. Sham
sections demonstrated diffuse immunoreactivity within the grey
matter with greater intensity observed within the dorsal horn
resulting in a median ranking of 7 (Figure 6). At 5 and 24 hours
post-SCI within the injury epicentre, a significant increase in NK1
receptor immunoreactivity to a median ranking to 9 was observed
within the injury epicentre in both treatment groups (vehicle =
p,0.01, NAT = p,0.05–0.01). Such immunoreactivity remained
elevated in both treatment groups on day 3 post-SCI. By 24 hours
post-SCI, the adjacent segments also demonstrated a slight
increase in NK1 expression centrally within the grey matter in
both groups. However by day 3, a slight reduction in NK1
immunoreactivity within these segments was observed in both
groups (median = 5). By 2 weeks post-SCI, the loss of tissue made
it difficult to assess NK1 immunoreactivity in the injury epicentre,
whereas NK1 immunoreactivity had further decreased in the
adjacent segments of both groups, recording a median ranking of 4
(rostral = p,0.05, caudal p,0.001).
3.5.5. NK1 immunoreactivity – Perivascular. Sham sec-
tions demonstrated faint NK1 receptor immunoreactivity sur-
rounding the vasculature with a median ranking of 4 (Figure 7).
Due to severe tissue disruption, NK1 immunoreactivity was not
assessed within the injury epicentre. A slight increase in NK1
immunoreactivity was observed within the adjacent segments of
both treatment groups at 5 hours post-SCI. Further increases were
observed at 24 hours post-SCI within the caudal segment
recording a median ranking of 7 for both treatment groups,
whilst the rostral segment was only slightly increased to a median
ranking of 6. By day 3, NAT treated caudal segments remained at
a median of 7, whereas vehicle treated animals had slightly
reduced further to 6, although this was still increased compared to
shams. Similarly, within the rostral segment NAT treatment
resulted in slightly greater immunoreactivity compared to both
vehicle and sham, whereas vehicle treated animals had compara-
ble NK1 immunoreactivity to shams. Vehicle treated animals
remained at sham levels at 2 weeks post-SCI in both sections,
whilst NAT treatment still recorded above sham levels (rostral
median = 5; caudal median 6).
3.5.6. Albumin immunoreactivity. Albumin immunoreac-
tivity was assessed to quantify the effect of NAT administration on
Figure 3. H&E staining demonstrates the morphological changes within the injury epicentre from 5 hours to 2 weeks post-SCI.
Hemorrhage was predominant within 24 hours post-SCI, with marked tissue loss observed by 2 weeks post-SCI. No differences were observed
between vehicle and NAT treatment groups. Cross section scale bar = 1 mm, high magnification scale bar = 100 mm.
doi:10.1371/journal.pone.0098364.g003
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the extent of BSCB permeability following SCI (Figure 8). Sham
sections of spinal cord demonstrated minimal albumin immuno-
reactivity with a DABwt% of 4.760.42, indicating that sham
surgery did not disrupt the BSCB. Following injury, a significant
increase in albumin immunoreactivity was observed within the
injury epicentre and became maximal at 24 hours post-SCI
reaching 24.6462.77 DABwt% (p,0.001). Albumin immunore-
activity then decreased over time, although was still significantly
greater than shams at 2 weeks (p,0.001). The NAT treated
animals had a similar expression of albumin to vehicle treated
animals in the injury epicentre, although they recorded signifi-
cantly greater albumin than vehicle treated animals at day 3 (p,
0.05). However by 2 weeks, they had decreased below vehicle
treated animals but were still had significantly greater albumin
than sham (p,0.05). Similarly, the adjacent segments demon-
strated maximal increases at 24 hours post-SCI for both treatment
groups (p,0.001), with a decrease over time so that by 2 weeks
both groups had returned to sham levels. Moreover, NAT treated
animals were comparable to vehicles at all assessment times in the
adjacent segments.
3.5.7. Microglial immunoreactivity (ISOB4) - White
Matter. Sham sections demonstrated low numbers of resting
microglia with long fine processes. After injury, small numbers of
microglia were observed within the injury epicentre of both
treatment groups (Figure 9A). At 24 hours post-SCI many cells
with a small round phenotype suggestive of phagocytic activity can
be seen. Furthermore, increased numbers of immunoreactive cells
can also be seen within the adjacent segments at this time. At 3
days post-SCI, tissue loss is apparent and further increases in
immunoreactive cells are seen within the injury epicentre in both
Figure 4. Assessment of the effect of NAT treatment on SP immunoreactivity within the dorsal horn region following SCI. Ranking of
SP immunoreactivity within the injury epicentre (B) and at 10 mm rostral (A) and 10 mm caudal (C). Sham sections demonstrated moderate SP
immunoreactivity (D). At 5 hours post-SCI reduced immunoreactivity was observed in both vehicle and NAT treatment groups within the injury
epicentre (E = Vehicle, F =NAT), whilst a slight reduction was apparent within the adjacent segments (G= Vehicle, H =NAT). However, a significant
loss was observed by 2 weeks post-SCI within the injury epicentre (I = Vehicle, J =NAT) and within the adjacent segments (K = Vehicle, L =NAT).
Higher magnification images clearly demonstrate this difference (M= sham, N=2 week Vehicle adjacent, O = 2 week NAT adjacent). Low
magnification scale bar = 1 mm, High magnification scale bar = 200 mm. Dashed line (A–C) represents sham median.
doi:10.1371/journal.pone.0098364.g004
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treatment groups. By 2 weeks post-SCI greater tissue loss is
apparent and florid microglia are present within the white matter,
becoming amoeboid in shape by 2 weeks post-SCI. At this time,
the adjacent segments of spinal cord also demonstrate increased
microglia immunoreacitivty, with many amoeboid cells apparent
within the white matter of both treatment groups. No differences
in microglia immunoreactivity were observed between vehicle and
NAT treated animals.
3.5.8. Microglial immunoreactivity (ISOB4) - Grey
Matter. Sham sections again demonstrate low numbers of
resting microglia with fine long processes (Figure 9B). At 5 hours
post-SCI, hemorrhage is visible in addition to small round
immunoreactive cells, suggestive of phagocytic activity, present
within the injury epicentre of both treatment groups. At 24 hours
post-SCI florid microglia can be seen within the injury epicentre
whilst the adjacent segments also demonstrate increased microglia
particularly surrounding the blood vessels within both treatment
groups. At 3 days post-SCI greater tissue loss was observed within
the injury epicentre with many immunoreactive cells still present,
and becoming larger in size. The adjacent segments demonstrated
numerous activated microglia that appear ramified in nature. By 2
weeks post-SCI increased tissue loss was observed within the injury
epicentre with larger phagocytic cells apparent within both vehicle
and NAT treated sections. The adjacent segments similarly
demonstrate florid microglial activity with many observed as fully
ramified and amoeboid in appearance, representing phagocytic
activity. No differences in microglial immunoreactivity between
vehicle and NAT treated groups were observed.
3.5.9. AQP4 immunoreactivity - Perivascular
region. Sham sections of spinal cord demonstrated faint
AQP4 immunoreactivity surrounding the vasculature within the
grey matter, assessed as a median ranking of 3 (Figure 10). Due to
severe tissue disruption the injury epicentre was not assessed.
Following injury increased AQP4 immunoreactivity was observed
by 5 hours and reached a median ranking of 6 by 24 hours post-
SCI. A slight decrease was observed at 3 days post-SCI in the
caudal section, whereas the rostral section still ranked 6. A further
decrease to below sham levels was apparent by 2 weeks (rostral
= 2; caudal = 1). NAT treatment had a similar pattern of
immunoreactivity to vehicle treated animals in the rostral section,
apart from on day 3 when they ranked slightly less (median = 4).
Within the caudal section, NAT treated animals recorded slightly
higher than vehicles at 5 hours, but then decreased over time so
that they were less than vehicles at 24 hours but similar at 3 days
and 2 weeks.
3.5.10. AQP4 immunoreactivity - Central Canal
region. Sham sections of spinal cord demonstrated faint
AQP4 immunoreactivity in the ependymal cells of the central
canal with a median ranking of 3 (Figure 10). The injury epicentre
was too disrupted to accurately assess AQP4 immunoreactivity.
Following injury an increase was observed in the rostral section by
5 hours (median = 4.5) with a slightly further rise to 5 at 24 hours
and 3 days before returning to sham levels at 2 weeks. In contrast,
NAT treated animals had maximal AQP4 immunoreactivity in
this section by 5 hours (median = 5), which remained until day 3
when a reduced ranking of 4 was recorded. A further decrease was
seen at 2 weeks, although they were still just above shams (median
3.5). Within the caudal section, AQP4 was not increased until
24 hours when a median ranking of 6 was recorded in the vehicle
treated animals. AQP4 then declined over time to be near to sham
Figure 5. Assessment of the effect of NAT treatment on SP immunoreactivity within the perivascular region following SCI. Ranking of
SP immunoreactivity at 10 mm rostral (A) and 10 mm caudal (B) to the injury epicentre. Sham sections demonstrated moderate SP immunoreactivity
(C). At both 5 and 24 hours post-SCI a slight decrease was observed within both segments of vehicle and NAT treatment groups. However at 3 days
post-SCI NAT treated sections at both 10 mm rostral (E) and caudal (G) demonstrated a return to sham levels whilst vehicle treated remained reduced
(D =10 mm rostral; F = 10 mm caudal). *denotes p,0.05, **denotes p,0.01, ***denotes p,0.001, sham median ranking indicated by the dashed line.
Scale bar = 25 mm.
doi:10.1371/journal.pone.0098364.g005
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levels by 2 weeks. In contrast, NAT treatment resulted in a
increase in AQP4 by 5 hours recording a median ranking of 5,
however then declined to 4 at 24 hours and had returned to sham
levels by day 3. No significant differences were observed between
treatment groups at any assessment time.
Discussion
The present study has demonstrated that administration of the
NK1 receptor antagonist, NAT, does not reduce BSCB perme-
ability, edema, ITP or significantly improve neurological function
following SCI. These results suggest that SP mediated neurogenic
inflammation does not play a major role in the acute development
of such injury processes following traumatic SCI. However, a
release of SP was observed, demonstrated by reduced SP
immunoreactivity, whilst perivascular NK1 receptor immunore-
activity initially increased before decreasing, which is suggestive of
NK1 receptor activation and internalisation. This reflects mani-
festation of SP mediated neurogenic inflammation, albeit that
neurogenic inflammation may not be the predominant driver of
these injury processes in the acute phase of SCI.
Although only a bolus dose of NAT was administered on the
day of surgery, and for two consecutive days for survival times of 3
days or more, such dosage regimes have previously been used in
acute CNS injury with highly beneficial outcomes [13,17,22].
Indeed administration of an NK1 receptor antagonist at 30
minutes post-TBI reduced barrier permeability, edema and
improved functional outcome, demonstrating that inhibition of
SP effects was possible despite a 30 minute delay post-injury
[13,17]. It is unlikely that a shorter timeframe for pharmacological
intervention would be clinically relevant. Furthermore, whilst
NAT is not barrier permeable, our results demonstrate that the
BSCB was disrupted for at least 5 hours post-SCI. Given the
severe extent of hemorrhage and destruction of vasculature
observed at the site of impact, intravenous administration may
have not provided sufficient delivery of NAT. Nonetheless, some
differences between vehicle and NAT treated groups were
observed in the current study beyond the injury site, indicating
that NAT administration was likely successfully delivered central-
ly. A more direct route of administration, such as an injection into
the intrathecal space may provide a more efficient method of
administration for future investigations. Given the highly pre-
served nature of NK1 receptors across different vertebrate species
[30], it is unlikely that any lack of effectiveness of NAT treatment
was due to low affinity for the rabbit NK1 receptor.
Whilst two isoforms of the NK1 receptor exist, a long complete
isoform and a truncated isoform, the binding site of the antagonist
is identical in both, and thus the NK1 receptor antagonist used in
the current study would be equally effective on both isoforms.
However, the long NK1 isoform is known to predominate within
the CNS whilst the truncated isoform is most represented within
peripheral tissue [31]. Additionally, consideration must be given to
related tachykinin receptors, the NK2 receptor and NK3 receptor.
Our results do not exclude the possibility that the NK2 or NK3
receptors might play an important role and that inhibition of these
receptors may be beneficial to outcome after SCI. However, SP
Figure 6. The effect of NAT administration on NK1 receptor immunoreactivity within the grey matter following SCI. Ranking of NK1
receptor immunoreactivity at 10 mm rostral (A), within the injury epicentre (B) and at 10 mm caudal (C). At 24 hours post-SCI a significant increase
was observed within the injury epicentre (E = vehicle and F =NAT), whilst adjacent segments demonstrated a slight increase (G = vehicle and
H=NAT). By 2 weeks post-SCI tissue loss was too great to assess NK1 immunoreactivity within the injury epicentre (I-vehicle, J-NAT) although
adjacent segments had reduced immunoreactivity (K-vehicle, L-NAT). No differences were observed between treatment groups at any time point.
*denotes p,0.05, **denotes p,0.01, ***denotes p,0.001, sham median ranking indicated by the dashed line (A,B & C). Scale bar = 1 mm.
doi:10.1371/journal.pone.0098364.g006
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binds preferentially to the NK1 receptor [32], and it is only
activation of this receptor that is thought to result in the initiation
of neurogenic inflammation. Indeed, It has been demonstrated
that the NK2 and NK3 receptors have no direct role in plasma
protein extravasation within the CNS [33].
After receiving 3 consecutive daily doses of NAT or saline, NAT
treated animals demonstrated a trend for greater perivascular and
dorsal horn SP immunoreactivity than vehicle treated animals.
Such increases in SP may be explained by the presence of an NK1
autoreceptor, which is thought to regulate SP release through a
negative feedback loop [34,35]. In the current study, blockade of
the NK1 autoreceptor due to NAT administration would prevent
SP from exerting negative feedback on its own synthesis and
release, resulting in greater expression of SP. However, the
comparative increase in SP would not have been functional, as
blockade of the NK1 receptor with NAT prevents SP from
binding and mediating downstream effects.
Interestingly, at 3 days post-injury NAT treatment resulted in
significantly higher BSCB permeability compared to vehicle as
assessed by albumin. This finding paradoxically implies that
inhibition of the NK1 receptor resulted in greater BSCB
permeability. Such results are in contrast to previous studies
where NAT treatment resulted in reduced BSCB permeability
following TBI and stroke [13,22]. These findings imply that
despite similar secondary injury processes arising following SCI,
the role of SP may be vastly different in SCI than its role in other
acute CNS injuries. One important difference may be the extent of
primary mechanical damage, resulting in severe hemorrhage.
Previous studies within our group have demonstrated that in
severe subarachnoid hemorrhage, NAT administration worsened
outcome [36]. These combined results suggest that in models of
severe hemorrhage, the primary induced tissue and vasculature
damage may dominate over SP mediated neurogenic inflamma-
tion in the development of BSCB permeability. Furthermore, as
the current study provided evidence that NAT treatment
worsened BSCB permeability, SP may actually play a protective
role in such severe hemorrhage models. Indeed, a recent study
demonstrated that SP treatment promoted a more anti-inflamma-
tory environment following SCI by inducing interlukin-10 and M2
macrophages whilst suppressing nitric oxide synthase and tumour
necrosis factor-a [37]. Our own results demonstrate an increase in
microglial activity following SCI, though predominantly phago-
cytic in nature, with no differences between treatment groups. In
addition, intrathecal administration of a SP antagonist has been
shown to cause a marked decrease in spinal cord blood flow
(SCBF) [38] and likely contributed to further damage and BSCB
permeability by promoting an ischemic environment. These
findings together with the current study suggest that SP may be
beneficial following acute SCI.
Regardless of the role of SP following SCI, edema remains a
serious complication leading to raised ITP [39,40], reduced SCBF
[9,40] and myelin damage [1]. Indeed, numerous studies have
shown that the extent of edema corresponds to the degree of
functional deficits observed following injury [41,42,43,44,45]. The
Figure 7. The effect of NAT administration on NK1 receptor immunoreactivity within the perivascular region following SCI. NK1
receptor immunoreactivity ranking at 10 mm rostral (A) and caudal (B). Sham sections demonstrated faint immunoreactivity surrounding the
vasculature (C). Notably, at 24 hours post-SCI a marked increase was observed in both vehicle (D) and NAT (E) treatment groups. By 2 weeks post-SCI
at 10 mm caudal vehicle treated (F) returned to sham levels, whilst NAT treated remained elevated (G). Median sham ranking indicated by the dashed
line (A&B).
doi:10.1371/journal.pone.0098364.g007
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present study demonstrated increased edema associated with
raised ITP following injury, which was maximal at 3 days post-
SCI. Furthermore, at this time it was apparent that the adjacent
segments, uninjured by the balloon compression, also demon-
strated significant increases in edema. Therefore, substantial
rostrocaudal spread of edema had occurred following the balloon
compression model by 3 days post-SCI. However, albumin
immunoreactivity, a marker of BSCB permeability, was maximal
at 24 hours post-SCI with a reduction observed at 3 days post-SCI
within the adjacent segments. Therefore, significant disparity exists
between BSCB permeability and edema formation, indicating that
the rostrocaudal spread of edema was not due to BSCB disruption
and thus not vasogenic in nature. These results further suggest that
neurogenic inflammation is not primarily responsible for the
developed edema and may account for the ineffectiveness of NAT
administration to reduce edema.
It is possible that the spread of edema may be a compensatory
mechanism to reduce the edema present within the injury
epicentre. Alternatively, the BSCB may in fact still remain
permeable to smaller molecules than albumin. Previous studies
have employed alternative smaller tracers of extravasation such as
hydrazide [46], horseradish peroxidase [10,47,48], protein lucif-
erase [49], and iodine [4,50] and found greater extension of BSCB
permeability. Alternatively, such increases in edema may be due to
an ultrafiltration mechanism rather than extravasation as previ-
ously described by Nemecek and colleagues [7]. Such ultrafiltra-
tion may be aided by reduced blood flow and severe hemorrhage.
As NAT treatment has no ability to reduce hemorhage and SP
antagonists can markedly reduce SCBF [38], the greater edema
within the adjacent segments of NAT treated animals may be due
to increased ultrafiltration. Alternatively, in the absence of BSCB
disruption, the increased edema may be facilitated by AQP4 water
channels.
Indeed, within the current study, AQP4 immunoreactivity was
increased following injury at similar times to maximal edema.
Although such an increase implies that AQP4 may facilitate
edema development, NAT administration resulted in a slight
increase in edema and a concurrent reduction in AQP4
immunoreactivity. Therefore, injury induced increases in AQP4
may actually be a compensatory mechanism to assist in fluid
clearance. These changes in AQP4 and edema formation contrast
to that in TBI, where injury reduced AQP4 expression and NAT
Figure 8. The effect of NAT treatment on albumin immunoreactivity following SCI. Albumin immunoreactivity at 10 mm rostral (A), within
the injury epicentre (B) and at 10 mm caudal (C). Sham sections (D) demonstrated minimal immunoreactivity. Immunoreactivity was significantly
increased at both 5 and 24 hours post-SCI. Representative images at 24 hours are shown within the injury epicentre (E-vehicle, F-NAT) and adjacent
segment (G-vehicle, H-NAT). By 3 days post-SCI albumin immunoreactivity began to reduce within the injury epicentre (I-vehicle, J-NAT) and adjacent
segment (K-vehicle, L-NAT), though NAT treatment resulted in significantly greater albumin immunoreactivity when compared to vehicle. Albumin
immunoreactivity reduced further by 2 weeks post-SCI within the injury epicentre (M-vehicle, N-NAT), returning to sham levels within the adjacent
segments (O-vehicle, P-NAT). *denotes p,0.05, **denotes p,0.01, ***denotes p,0.001 when compared to sham. Mean sham values indicated by the
dashed line. Scale bar = 1 mm.
doi:10.1371/journal.pone.0098364.g008
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treatment restored AQP4 levels, whilst reducing edema [28].
These opposing effects of NAT treatment in TBI and SCI further
illustrate the differences in their injury mechanisms. Moreover,
these results demonstrate that the relationship between SP and
AQP4 warrants further investigation. Taken together, these results
demonstrate that AQP4 may play an essential role in the
elimination of excess fluid. Indeed, previous investigations have
similarly demonstrated that AQP4 plays an integral role in
facilitating water clearance following SCI [2,51,52]. However, to
date, almost all studies of AQP4 following SCI have assessed its
function through altered expression [2,51], or employed AQP4-
null mice [12,52]. As such, further investigation to fully elucidate
the role of AQP4 following SCI is required. Ideally, this could be
through the pharmacological modulation of the AQP4 water
channels, which may then be utilized as a novel therapeutic
intervention.
Conclusions
The current study has demonstrated that despite a release of SP
and therefore induction of SP mediated neurogenic inflammation,
the severe primary damage that results in destruction of
vasculature and hemorrhage may play a greater role in BSCB
disruption, subsequent edema development and associated tissue
damage and functional deficits following traumatic SCI. Thus,
administration of the NK1 receptor antagonist, NAT, did not
reduce BSCB permeability, edema, ITP, or improve neurological
function following SCI. In contrast, SP may actually play a
beneficial role in reducing this ongoing damage associated with
traumatic SCI.
Figure 9. The effect of NAT administration on microglial immunoreactivity following SCI within the white matter (A) and grey
matter (B). Sham sections demonstrate minimal microglial immunoreactivity in both the white and grey matter. Within the white matter microglia
immunoreactivity is maximal by 2 weeks post-SCI within the injury epicentre and adjacent segment for both treatment groups. Within the grey
matter, many small round microglia can be seen within the injury epicentre, increasing in size by 2 weeks post-SCI. Within the adjacent segment of
the grey matter many ramified microglia can be seen by 3 days post-SCI and becoming amoeboid in shape by 2 week post-SCI. No differences
between treatment groups were observed. Scale bar (A) = 200 mm, (B) = 50 mm.
doi:10.1371/journal.pone.0098364.g009
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Figure 10. The effect of NAT administration on perivascular and ependymal AQP4 immunoreactivity following SCI. Ranking of
perivascular AQP4 immunoreactivity at 10 mm rostral (A) and 10 mm caudal (B). Sham sections demonstrated faint immunoreactivity surrounding
the vessels (C). Increased immunoreactivity can be seen at 24 hours following both vehicle (D) and NAT (E) treatment. Reduced immunoreacticity
below sham levels was observed at 2 weeks (H-vehicle, I-NAT). Dashed line indicated mean sham values. Ranking of ependymal AQP4
immunoreactivity at 10 mm rostral (H) and 10 mm caudal (I). Sham sections demonstrated faint immunoreactivity within the ependymal cells of the
central canal (J). At 24 hours post-SCI increases were apparent, with greater increases in the caudal segments of vehicle treated sections (K) than NAT
treated (L). By 2 weeks post-SCI both treatment groups demonstrated comparable AQP4 immunoreactivity to sham levels (M-vehicle, N-NAT). Scale
bars = 25 mm.
doi:10.1371/journal.pone.0098364.g010
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